Clene Sees Path Forward For ALS Candidate Despite Late-Stage Trial Failure
Touts Survival Signal
The US firm’s nanoparticle candidate has disappointed in a late-stage ALS trial but experts say secondary survival data could prove a silver lining given an increasingly flexible US regulatory environment.
